Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
TScan Therapeutics, Inc. | 10%+ Owner | Pre-funded Warrant (right to buy) | 5M | $35.6M | $7.13 | Apr 19, 2024 | Indirect |
TScan Therapeutics, Inc. | 10%+ Owner | Common stock, $0.0001 par value per share Common Stock | 5.24M | $13.2M | $2.51 | May 31, 2023 | Indirect |
TScan Therapeutics, Inc. | 10%+ Owner | Common Stock | 5.22M | $13.1M | $2.51 | May 31, 2023 | Indirect |
Passage BIO, Inc. | 10%+ Owner | Common stock, $0.0001 par value per share | 8.43M | $8.17M | $0.97 | Aug 7, 2024 | Indirect |
TScan Therapeutics, Inc. | 10%+ Owner | Common stock, $0.0001 par value per share | 5.25M | May 31, 2023 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PASG | Passage BIO, Inc. | Aug 7, 2024 | 0 | $0 | 3 | Aug 9, 2024 | 10%+ Owner |
TCRX | TScan Therapeutics, Inc. | Apr 19, 2024 | 1 | $35.6M | 4 | Apr 23, 2024 | 10%+ Owner |
TCRX | TScan Therapeutics, Inc. | May 31, 2023 | 3 | -$64K | 4 | Jun 2, 2023 | 10%+ Owner |
TCRX | TScan Therapeutics, Inc. | May 31, 2023 | 0 | $0 | 3 | Jun 2, 2023 | 10%+ Owner |